Novo Nordisk, Ozempic
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...
U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they ...
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to ...
Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, was set to grill ...
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of ...
5h
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Patients taking Ozempic were about 60% less likely to have an opioid overdose compared to those taking other diabetes drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback